keyword
MENU ▼
Read by QxMD icon Read
search

oxybutynin

keyword
https://www.readbyqxmd.com/read/27878051/anticholinergics-for-overactive-bladder-temporal-trends-in-prescription-and-treatment-persistence
#1
Christopher J D Wallis, Colin Lundeen, Nicole Golda, Hilary Brotherhood, Peter Pommerville, Lesley Carr
INTRODUCTION: We sought to understand the contemporary pharmacologic management of overactive bladder (OAB) in a single-payer system. We examined temporal trends in the use of anticholinergic medications and assessed whether the likelihood of patients changing their anticholinergic therapy was predicted by their current therapy. METHODS: We conducted a retrospective, population-based analysis of prescription records from the PharmaNet database in BC, Canada. We identified patients treated with one or more anticholinergic prescriptions between 2001 and 2009...
August 2016: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/27872944/-multiple-eccrine-hidrocystomas-on-the-lower-forehead-and-nose-of-a%C3%A2-60-year-old-man
#2
J K Winkler, W Hartschuh, A Enk, F Toberer
Multiple eccrine hidrocystomas are benign cystic skin lesions which originate from the sweat gland ducts and typically affect women's midfacial area. Sweating may lead to an increase in size of the translucent papules. In some cases hidrocystomas are associated with other diseases such as Parkinson's disease. Treatment options include laser, topical and systemic anticholinergic drugs (glycopyrrolate, clonidine, atropine, and oxybutynin), whereby therapeutic success is limited in most cases.
November 21, 2016: Der Hautarzt; Zeitschrift Für Dermatologie, Venerologie, und Verwandte Gebiete
https://www.readbyqxmd.com/read/27845692/-expert-opinion-about-the-use-of-transdermic-oxybutynin-in-spain-for-the-treatment-of-adult-overactive-bladder
#3
Carlos Müller-Arteaga, Salvador Arlandis Guzmán, María Fernanda Lorenzo Gómez, Carlos Errando-Smet, Raquel González López, Javier Cambronero Santos, José Luis Gutiérrez Baños, Manuel Sánchez Marcos, Antonio Ortiz Gamiz, Sergio Merino Salas, Roberto Martínez Rodriguez, Ivan Olano Grasa
OBJECTIVES: To define the different characteristics of transdermal oxybutynin (TO) for the treatment of overactive bladder in adults, to know the barriers for the use of this drug and to establish proposals to minimize these barriers. METHODS: Local sessions were held with 111 urologists from all over the country divided into 12 sessions. They were moderated by a brainstorming technique led by an external consultant. RESULTS: 75% of experts believe that tolerability and clinical efficacy (50%) are the most important attributes to choose this formulation, being the lack of scientific publications the least valued (12%)...
November 2016: Archivos Españoles de Urología
https://www.readbyqxmd.com/read/27760081/extended-release-oxybutynin-therapy-for-vasomotor-symptoms-in-women-a-randomized-clinical-trial
#4
James A Simon, Tatiana Gaines, Katherine D LaGuardia
OBJECTIVE: Assess effects of once-daily, extended-release oxybutynin chloride on frequency and severity of vasomotor symptoms in healthy, postmenopausal symptomatic women. METHODS: A 12-week, multicenter, double-blind, placebo-controlled, phase 2 clinical trial randomized naturally postmenopausal women experiencing at least seven moderate-to-severe vasomotor symptoms daily to oxybutynin 15 mg once daily (n = 73) or placebo (n = 75). Co-primary outcomes were the change from baseline to week 12 in the frequency and severity of moderate-to-severe vasomotor symptoms...
November 2016: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/27738922/a-short-review-of-drug-food-interactions-of-medicines-treating-overactive-bladder-syndrome
#5
Paweł Paśko, Tomasz Rodacki, Renata Domagała-Rodacka, Danuta Owczarek
Background Overactive bladder syndrome is a condition where one or more of the symptoms such as pollakiuria, urgent need to urinate, nocturia and urinary incontinence is observed. Its prevalence ranges between 7 and 27 % in men and 9-43 % in women. The role of a pharmacist is to educate the patient on medications administration scheme, and drug interactions with particular food or food components. Aim of the review To assess a potential impact of food and fruit juice on the pharmacokinetic and therapeutic effects of medications used in treating overactive bladder syndrome...
December 2016: International Journal of Clinical Pharmacy
https://www.readbyqxmd.com/read/27681701/antimuscarinic-medication-use-in-elderly-patients-with-overactive-bladder
#6
Nandita Kachru, Sneha Sura, Satabdi Chatterjee, Rajender R Aparasu
BACKGROUND: Antimuscarinic medications are the first-line pharmacological treatment for overactive bladder (OAB); however, little is known about the utilization pattern of antimuscarinic agents in elderly patients with OAB. OBJECTIVE: This study examined the prevalence and predictors of antimuscarinic medication prescribing in elderly patients with OAB, using national ambulatory survey data. METHODS: This cross-sectional study utilized the 2009-2010 National Ambulatory Medical Care Survey and the outpatient component of the National Hospital Ambulatory Medical Care Survey...
October 2016: Drugs & Aging
https://www.readbyqxmd.com/read/27680597/role-of-gabapentin-and-anticholinergics-in-management-of-neurogenic-bladder-after-repair-of-spina-bifida-a-randomized-controlled-study
#7
Vedarth Dash, Monika Bawa, J K Mahajan, Ravi P Kanojia, Ram Samujh, Kln Rao
BACKGROUND: Anticholinergics are well established in the management of neurogenic bladders. However, some patients do have sub-optimal response or severe side effects. This study is designed to assess and compare efficacy of gabapentin with oxybutynin in neurogenic bladders after surgery for spina bifida. METHODS: Patients were randomized into three groups after urodynamic studies and started on oxybutynin, gabapentin, and combination of both, respectively. Thorough clinical and urodynamic reassessment was done at 6months and one year after starting treatment...
September 15, 2016: Journal of Pediatric Surgery
https://www.readbyqxmd.com/read/27631556/development-of-a-novel-simplified-pbpk-absorption-model-to-explain-the-higher-relative-bioavailability-of-the-oros%C3%A2-formulation-of-oxybutynin
#8
Andrés Olivares-Morales, Avijit Ghosh, Leon Aarons, Amin Rostami-Hodjegan
A new minimal Segmented Transit and Absorption model (mSAT) model has been recently proposed and combined with intrinsic intestinal effective permeability (P eff,int ) to predict the regional gastrointestinal (GI) absorption (f abs ) of several drugs. Herein, this model was extended and applied for the prediction of oral bioavailability and pharmacokinetics of oxybutynin and its enantiomers to provide a mechanistic explanation of the higher relative bioavailability observed for oxybutynin's modified-release OROS® formulation compared to its immediate-release (IR) counterpart...
September 8, 2016: AAPS Journal
https://www.readbyqxmd.com/read/27631249/strategies-for-the-prevention-of-catheter-related-bladder-discomfort-a-prisma-compliant-systematic-review-and-meta-analysis-of-randomized-controlled-trials
#9
Baoji Hu, Chengbao Li, Mengzhi Pan, Ming Zhong, Yu Cao, Nannan Zhang, Hongbin Yuan, Hongwei Duan
BACKGROUND: The ideal measures to prevent postoperative catheter-related bladder discomfort (CRBD) remain unestablished. We conducted the systematic review and meta-analysis to clarify the significance of potential interventions. METHODS: We followed the Preferred Reporting Items for Systematic review and Meta-Analysis statement guidelines, and searched databases from MEDLINE, EMBASE, and referred Cochrane Library for randomized clinical trials (RCTs) published before December 2014...
September 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27619779/optimum-dose-of-once-daily-oxybutynin-patch-in-japanese-patients-with-overactive-bladder-a-randomized-double-blind-trial-versus-placebo
#10
Osamu Yamaguchi, Eiji Uchida, Naruhito Higo, Hidenao Minami, Shigeo Kobayashi, Hiroyuki Sato
OBJECTIVE: To evaluate the efficacy, safety, and optimum dose of once-daily oxybutynin patch for overactive bladder. METHODS: A randomized double-blind trial was conducted in patients with overactive bladder symptoms for ≥24 weeks, who received an oxybutynin patch (73.5 or 105 mg) or placebo once daily for 8 weeks. The primary endpoint was the change in the daily frequency of micturition from baseline to the end of study. RESULTS: A total of 579 patients were randomized to the placebo group (n = 164), 73...
September 2016: Lower Urinary Tract Symptoms
https://www.readbyqxmd.com/read/27614759/intravesical-treatment-for-interstitial-cystitis-painful-bladder-syndrome-a-network-meta-analysis
#11
Wei Zhang, Xiaojing Deng, Chunyu Liu, Xu Wang
INTRODUCTION AND HYPOTHESIS: Interstitial cystitis/painful bladder syndrome (IC/PBS) is a chronic inflammatory condition of the submucosal and muscular layers of the bladder. So far, there is no effective and targeted treatment strategy for IC/PBS. This study aimed to assess the efficacy and safety of intravesical instillation treatment in IC/PBS patients. METHODS: We searched various databases up to October 2015. A network meta-analysis was performed to compare global response assessment (GRA) for different treatment strategies, including botulinum toxin A (BoNTA), bacillus Calmette-Guerin (BCG), resiniferatoxin (RTX), lidocaine, chondroitin sulfate (CS), oxybutynin, and pentosan polysulfate (PPS)...
September 10, 2016: International Urogynecology Journal
https://www.readbyqxmd.com/read/27579830/estimated-budget-impact-of-increased-use-of-mirabegron-a-novel-treatment-for-overactive-bladder
#12
Sinem Perk, Ronald C Wielage, Noll L Campbell, Timothy M Klein, Anthony Perkins, Linda M Posta, Thomas Yuran, Robert W Klein, Daniel B Ng
BACKGROUND: Oral pharmacological treatment for overactive bladder (OAB) consists of antimuscarinics and the beta-3 adrenergic agonist mirabegron. Antimuscarinic adverse events (AEs) such as dry mouth, constipation, and blurry vision can result in frequent treatment discontinuation rates, leaving part of the OAB population untreated. Antimuscarinics also contribute to a patient's anticholinergic cognitive burden (ACB), so the Beers Criteria recommends cautious use of antimuscarinics in elderly patients who take multiple anticholinergic medications or have cognitive impairment...
September 2016: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/27574750/estimated-budget-impact-of-increased-use-of-mirabegron-a-novel-treatment-for-overactive-bladder
#13
Sinem Perk, Ronald C Wielage, Noll L Campbell, Timothy M Klein, Anthony Perkins, Linda M Posta, Thomas Yuran, Robert W Klein, Daniel B Ng
BACKGROUND: Oral pharmacological treatment for overactive bladder (OAB) consists of antimuscarinics and the beta-3 adrenergic agonist mirabegron. Antimuscarinic adverse events (AEs) such as dry mouth, constipation, and blurry vision can result in frequent treatment discontinuation rates, leaving part of the OAB population untreated. Antimuscarinics also contribute to a patient's anticholinergic cognitive burden (ACB), so the Beers Criteria recommends cautious use of antimuscarinics in elderly patients who take multiple anticholinergic medications or have cognitive impairment...
September 2016: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/27497508/preliminary-experience-with-transdermal-oxybutynin-patches-for-hyperhidrosis
#14
M Bergón-Sendín, A Pulido-Pérez, L C Sáez-Martín, R Suárez-Fernández
BACKGROUND AND OBJECTIVE: Hyperhidrosis is very common and has a considerable impact on patients' quality of life. While oral oxybutynin is associated with good response rates, adverse effects are common and frequently cause patients to stop treatment. Following the recent launch of oxybutynin in a transdermal patch formulation in Spain, we undertook a preliminary study to assess treatment response and adverse effects in patients with hyperhidrosis. MATERIAL AND METHODS: This prospective study of 25 patients treated twice weekly with transdermal oxybutynin patches over 10 weeks assessed treatment response on 2 subjective scales: the Hyperhidrosis Disease Severity Scale (HDSS) and a visual analog scale (VAS) for sweating...
August 3, 2016: Actas Dermo-sifiliográficas
https://www.readbyqxmd.com/read/27373215/evaluating-use-of-higher-dose-oxybutynin-in-combination-with-desmopressin-for-refractory-nocturnal-enuresis
#15
Aaron Berkenwald, Jacqueline Pires, Pamela Ellsworth
INTRODUCTION: Nocturnal enuresis is a common pediatric condition with limited treatment options. In older children, pharmacologic therapy is often the preferred treatment. Pharmacologic therapies including desmopressin (DDAVP) or imipramine are effective in 40-50% of children. However, imipramine has serious safety concerns. Desmopressin in combination with a fixed dose anticholinergic has been shown to be useful in individuals who fail desmopressin monotherapy, but still fails to achieve success rates greater than 60%...
August 2016: Journal of Pediatric Urology
https://www.readbyqxmd.com/read/27371430/-a-retrospective-observational-and-multicentre-study-on-patients-with-hyperactive-bladder-on-treatment-with-mirabegron-and-oxybutinine-under-usual-clinical-practice-conditions
#16
A Sicras-Mainar, R Navarro-Artieda, A Ruiz-Torrejón, M Saez, G Coll-de Tuero, L Sánchez
OBJECTIVE: To evaluate therapeutic persistence, healthcare resources, medical costs and adverse events of oxybutynin and mirabegron treatments in patients with overactive bladder in routine medical practice. PATIENTS AND METHODS: An observational, retrospective, multicentre study was carried out using the records of patients attended to in 3 different geographic locations (Barcelona, Girona, Asturias). An analysis was made on the 2 study groups (oxybutynin and mirabegron)...
June 28, 2016: Semergen
https://www.readbyqxmd.com/read/27367752/combinational-effects-of-muscarinic-receptor-inhibition-and-%C3%AE-3-adrenoceptor-stimulation-on-neurogenic-bladder-dysfunction-in-rats-with-spinal-cord-injury
#17
Naoki Wada, Takahiro Shimizu, Shun Takai, Nobutaka Shimizu, Pradeep Tyagi, Hidehiro Kakizaki, Naoki Yoshimura
AIMS: To investigate the effects of combined therapy with an anticholinergic agent and a β3-adrenoceptor agonist on bladder dysfunction and proliferation-related molecule expression in rats with spinal cord injury (SCI). METHODS: The spinal cord was transected at the level of T8-9 in female Sprague-Dawley rats, which were divided into four groups; A: Vehicle, B: 10 mg/kg/day of oxybutynin, C: 10 mg/kg/day of mirabegron, and D: combined administration of oxybutynin and mirabegron...
July 1, 2016: Neurourology and Urodynamics
https://www.readbyqxmd.com/read/27286111/efficacy-of-tamsulosin-oxybutynin-and-their-combination-in-the-control-of-double-j-stent-related-lower-urinary-tract-symptoms
#18
Miguel Maldonado-Avila, Leopoldo Garduno-Arteaga, Rene Jungfermann-Guzman, Hugo A Manzanilla-Garcia, Emmanuel Rosas-Nava, Nestor Procuna-Hernandez, Alejandro Vela-Mollinedo, Luis Almazan-Trevino, Jose Guzman-Esquivel
INTRODUCTION AND OBJECTIVE: Indwelling double J ureteral stents are used routinely in the resolution of ureteral obstruction caused by different etiologies. Evaluation of urinary symptoms related to double-J stent, indicate that these affect 73-90% of patients. We conducted a prospective, randomized study, to evaluate the efficacy of tamsulosin, oxybutinin and combination therapy in improving the urinary symptoms. METHODS: Patients who underwent ureteral stent placement after ureterolithotripsy (total 51), were randomized into three groups: Group I: Tamsulosin 0...
May 2016: International Braz J Urol: Official Journal of the Brazilian Society of Urology
https://www.readbyqxmd.com/read/27282551/combined-low-dose-antimuscarinics-for-refractory-detrusor-overactivity-in-children
#19
A Fahmy, M Youssif, H Rhashad, I Mokhless, W Mahfouz
INTRODUCTION AND AIMS: Behavioral therapy and bowel management are the initial and mainstay treatments for overactive bladder (OAB). Antimuscarinic agents are initiated if these measures fail or symptoms are severe. This study reported the results of treatment with a high dosage of a single drug in children with refractory detrusor overactivity (DO). After the children maintained their previous antimuscarinic medication, a second antimuscarinic drug (trospium chloride) was added as a combination therapy...
August 2016: Journal of Pediatric Urology
https://www.readbyqxmd.com/read/27253972/current-and-future-pharmacotherapy-for-treating-overactive-bladder
#20
Ganesh Thiagamoorthy, Linda Cardozo, Dudley Robinson
INTRODUCTION: Drugs which prevent acetylcholine mediated involuntary detrusor contractions are the mainstay of overactive bladder(OAB) treatment but there are now several alternative therapeutic options available. AREAS COVERED: Current and future drug therapies for OAB are highlighted. These include novel antimuscarinic molecules (imidafenacin and tarafenacin); novel combination therapies with β3-adrenoceptor agonists or muscarinic agonists (tolenix) and a novel vaginal delivery method for oxybutynin...
July 2016: Expert Opinion on Pharmacotherapy
keyword
keyword
110797
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"